Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Large B-Cell, Diffuse

Explore clinical trials studying Lymphoma, Large B-Cell, Diffuse. Study availability and eligibility vary by location and protocol.

1,249 public trials 217 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Large B-Cell, Diffuse trial results

Active, Not Recruiting

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

NCT04661007

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Aichi Cancer Center Hospital Aichi, Japan
  • Chiba Cancer Center Chiba, Japan
  • National Cancer Center Hospital East Chiba, Japan
  • University of Fukui Hospital Fukui, Japan
View all 23 locations
View Trial Details
Active, Not Recruiting

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT01955499

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +21 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
View Trial Details
Active, Not Recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

NCT03038672

Conditions
ALK-Positive Large B-Cell Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +53 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Moffitt Cancer Center-International Plaza Tampa, Florida, United States
View all 33 locations
View Trial Details
Active, Not Recruiting

A Rollover Study of CC-122

NCT05688475

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +27 more
Locations
  • Local Institution - 100 New York, United States
  • Local Institution - 101 Nashville, Tennessee, United States
  • Local Institution - 102 Madison, Wisconsin, United States
  • Local Institution - 300 Bordeaux, France
View Trial Details
Active, Not Recruiting

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

NCT06014762

Conditions
DLBCL, DLBCL - Diffuse Large B Cell Lymphoma, DLBCL Arising From Follicular Lymphoma, +21 more
Locations
  • Loma Linda University Cancer Center Loma Linda, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • Advent Health Orlando Orlando, Florida, United States
  • Indiana University Indianapolis, Indiana, United States
View all 16 locations
View Trial Details
Active, Not Recruiting

Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy

NCT01829958

Conditions
Diffuse Large B-Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
View Trial Details
Active, Not Recruiting

A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

NCT07226752

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Affiliated Hospital of Hebei University Baoding, China
  • Beijing Cancer Hospital Beijing, China
  • Beijing Tongren Hospital, Capital Medical University Beijing, China
  • Peking University Third Hospital Beijing, China
View all 23 locations
View Trial Details
Active, Not Recruiting

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

NCT05429268

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Medical University Plovdiv Plovdiv, Bulgaria
  • Acibadem Cityclinica Mhat Tokuda Sofia, Bulgaria
  • Umhat Alexandrovska Sofia Sofia, Bulgaria
  • Umhat Sv. Ivan Rilski Ead Sofia, Bulgaria
View all 61 locations
View Trial Details

Related conditions